Drugmaker Acer To Pay $8.35M To End Investor Suit
Drugmaker Acer Therapeutics Inc. has agreed to pay $8.35 million to end investor claims that it misrepresented conversations it had with the U.S. Food and Drug Administration, which allegedly hurt investors...To view the full article, register now.
Already a subscriber? Click here to view full article